Drug Search Results
More Filters [+]

UB-851

Alternative Names: ub-851, ub851, ub 851
Latest Update: 2023-12-06
Latest Update Note: Clinical Trial Update

Product Description

For Renal Anemia; UB-851 (rhEPO) has been developed as a biosimilar product to Eprex¨. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02708914)

Mechanisms of Action: ERA Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: UBI Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for UB-851

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Anemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

P304-EPO

P3

Completed

Anemia

2021-10-01

45%

Recent News Events

Date

Type

Title